The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk and Eli Lilly. Analysts project the industry could rake in $150 billion in annual sales by the next decade.

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand for high-protein foods and fitness gear.